Prudential Financial Inc. lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 318,978 shares of the medical instruments supplier’s stock after selling 4,045 shares during the period. Prudential Financial Inc. owned 0.14% of Becton Dickinson and worth $62,504,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of BDX. Beach Investment Management LLC. purchased a new position in Becton Dickinson and during the 2nd quarter valued at about $2,218,000. Cullen Frost Bankers Inc. boosted its stake in shares of Becton Dickinson and by 1.7% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 80,338 shares of the medical instruments supplier’s stock worth $15,674,000 after purchasing an additional 1,335 shares during the last quarter. Norris Perne & French LLP MI boosted its stake in shares of Becton Dickinson and by 25.8% during the 2nd quarter. Norris Perne & French LLP MI now owns 57,278 shares of the medical instruments supplier’s stock worth $11,175,000 after purchasing an additional 11,739 shares during the last quarter. Tdam USA Inc. boosted its stake in shares of Becton Dickinson and by 7.8% during the 2nd quarter. Tdam USA Inc. now owns 20,578 shares of the medical instruments supplier’s stock worth $3,976,000 after purchasing an additional 1,488 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Becton Dickinson and by 9.3% during the 2nd quarter. Pictet Asset Management Ltd. now owns 246,404 shares of the medical instruments supplier’s stock worth $46,627,000 after purchasing an additional 21,022 shares during the last quarter. Hedge funds and other institutional investors own 75.53% of the company’s stock.
Several equities research analysts have issued reports on the stock. Zacks Investment Research cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Royal Bank of Canada reissued a “sector perform” rating and issued a $230.00 target price (up from $210.00) on shares of Becton Dickinson and in a research report on Friday, November 3rd. Morgan Stanley lifted their price target on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, KeyCorp began coverage on shares of Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $230.20.
Becton Dickinson and Co (NYSE BDX) traded up $1.89 during mid-day trading on Friday, reaching $227.71. 1,870,458 shares of the company’s stock traded hands, compared to its average volume of 1,265,714. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton Dickinson and Co has a 12-month low of $169.19 and a 12-month high of $229.68. The company has a market capitalization of $60,161.90, a price-to-earnings ratio of 48.97, a price-to-earnings-growth ratio of 1.76 and a beta of 1.07.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter in the previous year, the company posted $2.12 earnings per share. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. equities research analysts predict that Becton Dickinson and Co will post 10.66 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Investors of record on Friday, December 8th were issued a $0.75 dividend. The ex-dividend date was Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.32%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio is presently 64.52%.
TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/prudential-financial-inc-cuts-holdings-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.